Bokemeyer, C., Van Cutsem, E., Rougier, P., et al. (2012) Addition of Cetuximab to Chemotherapy as First-Line Treatment for KRAS Wild-Type Metastatic Colorectal Cancer: Pooled Analysis of the CRYSTAL and OPUS Randomised Clinical Trials. European Journal of Cancer, 48, 1466-1475. https://doi.org/10.1016/j.ejca.2012.02.057

has been cited by the following article:

• TITLE: Colorectal Cancer in Morocco: Is There a Correlation between the Epidemiological and Anatomopathological Profile and the RAS Status?

  AUTHORS: Imane Ait Kaikai, Meriem Belhouari, Hind Mchanter, Mouna Bourhafour, Tarik Chekrine, Zineb Bouchbika, Nadia Benchakroun, Hassan Jouhadi, Souha Sahraoui, Meriem Regragui, Samira Benayad, Mehdi Karkouri, Karima Bendahhou, Nezha Tawfiq

  KEYWORDS: Colorectal Cancer, RAS Status, Epidemiological and Anatomopathological Profile

  JOURNAL NAME: Open Access Library Journal, Vol.10 No.5, May 30, 2023

  ABSTRACT: Introduction: Colorectal cancer is the third most common cancer in Morocco. The profile of patients according to RAS status has been the subject of few studies in Morocco. The objective of our study is to evaluate the epidemiological, anatomopathological and molecular parameters of a Moroccan population according to RAS status and to search for a possible correlation between the latter and the RAS mutation. Material and Methods: This is a cross-sectional study conducted at the Mohamed VI Center for Cancer Treatment in Casablanca during the period from May 2015 to February 2021. Included were 282 patients with histologically confirmed colorectal cancer whose RAS status was known and significant. The main criteria studied were age, gender, personal and family history of colorectal cancer or other types of cancers, anatomo-pathological characteristics (tumor site, histological type, tumor size, lymph node invasion, laterality, differentiation grade, stage, BRAF, MSI…), therapeutic modalities and evolutionary data. Results: 47.2% of patients were RAS Wild Type and 52.8% of whom were RAS mutated with a predominance of KRAS mutation (92.6%). The analysis of the association between the RAS mutation and the epidemiological and anatomopathological characteristics of the patients did not reveal any statistically significant correlation, except for two parameters: age (p = 0.035) and degree of differentiation (p Conclusion: The latter was not correlated with the anatomopathological and epidemiological characteristics of the patients except for the advanced age and the well-differentiated type of colorectal adenocarcinoma.